Jie Sun1, An Shi1, Zhen Tong1, Wei Xue2. 1. Department of Urology, Renji Hospital affiliated to Shanghai Jiao Tong University, Medical School, No 160, PuJian Road, Pudong New District, Shanghai, 201200, China. 2. Department of Urology, Renji Hospital affiliated to Shanghai Jiao Tong University, Medical School, No 160, PuJian Road, Pudong New District, Shanghai, 201200, China. xwrenji@126.com.
Abstract
OBJECTIVE: To evaluate the safety and feasibility of Holmium laser enucleation of the prostate (HoLEP) in patients receiving dual antiplatelet therapy (DAPT). METHODS: From March 2013 to August 2016, we retrospectively analyzed 1124 benign prostatic hyperplasia (BPH) patients undergoing HoLEP and divided into four groups: 56 cases receiving DAPT therapy (group A); 72 patients treated with continuous single antiplatelet (AP) therapy (group B); 41 patients treated with single AP therapy but intermittent during preoperative time (group C) and 955 cases had no AP therapy (group D). Patients' baseline characteristics, 1-year clinical outcomes, rates of postoperative bleeding and complications were presented in this study. RESULTS: All patients received successful operations and no severe postoperative complications occurred. Only one patient in Group D required transfusion. The enucleation time and catheterization time for the DAPT patients were the longest among four groups (p < 0.001, respectively). The overall complications rates within 30 days were 23.2% (13/56) in Group A, 27.8% (20/72) in Group B, 19.5% (8/41) in Group C, and 27.0% (258/955) in Group D, respectively (p = 0.678). By the 12 months, the international prostate symptom scores (IPSS), quality of life scores (QOL) and residual urine volume (RUV) in all groups have been significantly improved. CONCLUSION: HoLEP in patients receiving DAPT after coronary artery stunting showed similar results to those achieved in patients receiving single AP therapy or non-AP therapy. It can be a good option, which the urologists can offer to those patients with symptomatic benign prostatic hyperplasia refractory to medical treatment.
OBJECTIVE: To evaluate the safety and feasibility of Holmium laser enucleation of the prostate (HoLEP) in patients receiving dual antiplatelet therapy (DAPT). METHODS: From March 2013 to August 2016, we retrospectively analyzed 1124 benign prostatic hyperplasia (BPH) patients undergoing HoLEP and divided into four groups: 56 cases receiving DAPT therapy (group A); 72 patients treated with continuous single antiplatelet (AP) therapy (group B); 41 patients treated with single AP therapy but intermittent during preoperative time (group C) and 955 cases had no AP therapy (group D). Patients' baseline characteristics, 1-year clinical outcomes, rates of postoperative bleeding and complications were presented in this study. RESULTS: All patients received successful operations and no severe postoperative complications occurred. Only one patient in Group D required transfusion. The enucleation time and catheterization time for the DAPTpatients were the longest among four groups (p < 0.001, respectively). The overall complications rates within 30 days were 23.2% (13/56) in Group A, 27.8% (20/72) in Group B, 19.5% (8/41) in Group C, and 27.0% (258/955) in Group D, respectively (p = 0.678). By the 12 months, the international prostate symptom scores (IPSS), quality of life scores (QOL) and residual urine volume (RUV) in all groups have been significantly improved. CONCLUSION: HoLEP in patients receiving DAPT after coronary artery stunting showed similar results to those achieved in patients receiving single AP therapy or non-AP therapy. It can be a good option, which the urologists can offer to those patients with symptomatic benign prostatic hyperplasia refractory to medical treatment.
Entities:
Keywords:
Benign prostate hyperplasia; Dual antiplatelet therapy; Holmium laser enucleation of the prostate; Lower urinary tract symptoms
Authors: Peter J Gilling; Liam C Wilson; Colleen J King; Andre M Westenberg; Christopher M Frampton; Mark R Fraundorfer Journal: BJU Int Date: 2011-08-23 Impact factor: 5.588
Authors: Robert A Byrne; Patrick W Serruys; Andreas Baumbach; Javier Escaned; Jean Fajadet; Stefan James; Michael Joner; Semih Oktay; Peter Jüni; Adnan Kastrati; George Sianos; Giulio G Stefanini; William Wijns; Stephan Windecker Journal: Eur Heart J Date: 2015-06-12 Impact factor: 29.983
Authors: Debra E Irwin; Ian Milsom; Steinar Hunskaar; Kate Reilly; Zoe Kopp; Sender Herschorn; Karin Coyne; Con Kelleher; Christian Hampel; Walter Artibani; Paul Abrams Journal: Eur Urol Date: 2006-10-02 Impact factor: 20.096
Authors: Christian Gratzke; Alexander Bachmann; Aurelien Descazeaud; Marcus J Drake; Stephan Madersbacher; Charalampos Mamoulakis; Matthias Oelke; Kari A O Tikkinen; Stavros Gravas Journal: Eur Urol Date: 2015-01-19 Impact factor: 20.096
Authors: Marawan M El Tayeb; Joseph M Jacob; Naeem Bhojani; Elaine Bammerlin; James E Lingeman Journal: J Endourol Date: 2016-05-03 Impact factor: 2.942
Authors: Giorgio Bozzini; Matteo Maltagliati; Umberto Besana; Lorenzo Berti; Albert Calori; Maria Chiara Sighinolfi; Salvatore Micali; Jean Baptiste Roche; Ali Gozen; Alexander Mueller; Dimitry Pushkar; Evangelos Liatsikos; Marco Boldini; Carlo Buizza; Bernardo Rocco Journal: BMC Urol Date: 2021-02-23 Impact factor: 2.264